FDA Warns About Unapproved GLP-1 Weight Loss Drugs:
FDA Warns About Unapproved GLP-1 Weight Loss Drugs: What Patients Need to Know Published: June 2026 The U.S. Food and Drug Administration (FDA) has issued an updated safety communication warning consumers about the growing number of unapproved GLP-1 medications being sold for weight loss. While medications such as semaglutide and tirzepatide have transformed the
FDA Warns About Unapproved GLP-1 Weight Loss Drugs: Read More »